Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Lederer

Showing results (81-90 of 219) with videos related to

Pageof 22
Sort By:
BMJ Open Respiratory Research|June 11, 2019
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)Toby M Maher, Michael Kreuter, David J Lederer, et al.
The European Respiratory Journal|August 3, 2019
Circulating adhesion molecules and subclinical interstitial lung disease: the Multi-Ethnic Study of AtherosclerosisClaire F McGroder, Carrie P Aaron, Suzette J Bielinski, et al.
Chest|May 2, 2013
A prognostic model for 6-month mortality in elderly survivors of critical illnessMatthew R Baldwin, Wazim R Narain, Hannah Wunsch, et al.
Annals of the American Thoracic Society|April 15, 2021
Summary for Clinicians: Clinical Practice Guideline on Home Oxygen Therapy for Adults with Chronic Lung DiseaseYet H Khor, Katherine A Dudley, Derrick Herman, et al.
Chest|January 21, 2006
Osteoporosis in diffuse parenchymal lung diseaseCaralee E Caplan-Shaw, Selim M Arcasoy, Elizabeth Shane, et al.
Chest|November 20, 2008
Serum albumin concentration and waiting list mortality in idiopathic interstitial pneumoniaDavid A Zisman, Steven M Kawut, David J Lederer, et al.
Annals of the American Thoracic Society|October 26, 2016
Survival Benefit of Lung Transplantation in the Modern Era of Lung AllocationDavid M Vock, Michael T Durheim, Wayne M Tsuang, et al.
Annals of the American Thoracic Society|August 1, 2019
Angiotensin Receptor Blockers and Subclinical Interstitial Lung Disease: The MESA StudyWhitney D Gannon, Michaela R Anderson, Anna J Podolanczuk, et al.
The Lancet. Respiratory Medicine|October 4, 2019
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trialToby M Maher, Tamera J Corte, Aryeh Fischer, et al.
Respiratory Medicine|June 30, 2018
Collagen biomarkers and subclinical interstitial lung disease: The Multi-Ethnic Study of AtherosclerosisPurnema Madahar, Daniel A Duprez, Anna J Podolanczuk, et al.
Pageof 22

Showing results (81-90 of 219) with videos related to

Sort By:
Pageof 22
BMJ Open Respiratory Research|June 11, 2019
Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)Toby M Maher, Michael Kreuter, David J Lederer, et al.
The European Respiratory Journal|August 3, 2019
Circulating adhesion molecules and subclinical interstitial lung disease: the Multi-Ethnic Study of AtherosclerosisClaire F McGroder, Carrie P Aaron, Suzette J Bielinski, et al.
Chest|May 2, 2013
A prognostic model for 6-month mortality in elderly survivors of critical illnessMatthew R Baldwin, Wazim R Narain, Hannah Wunsch, et al.
Annals of the American Thoracic Society|April 15, 2021
Summary for Clinicians: Clinical Practice Guideline on Home Oxygen Therapy for Adults with Chronic Lung DiseaseYet H Khor, Katherine A Dudley, Derrick Herman, et al.
Chest|January 21, 2006
Osteoporosis in diffuse parenchymal lung diseaseCaralee E Caplan-Shaw, Selim M Arcasoy, Elizabeth Shane, et al.
Chest|November 20, 2008
Serum albumin concentration and waiting list mortality in idiopathic interstitial pneumoniaDavid A Zisman, Steven M Kawut, David J Lederer, et al.
Annals of the American Thoracic Society|October 26, 2016
Survival Benefit of Lung Transplantation in the Modern Era of Lung AllocationDavid M Vock, Michael T Durheim, Wayne M Tsuang, et al.
Annals of the American Thoracic Society|August 1, 2019
Angiotensin Receptor Blockers and Subclinical Interstitial Lung Disease: The MESA StudyWhitney D Gannon, Michaela R Anderson, Anna J Podolanczuk, et al.
The Lancet. Respiratory Medicine|October 4, 2019
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trialToby M Maher, Tamera J Corte, Aryeh Fischer, et al.
Respiratory Medicine|June 30, 2018
Collagen biomarkers and subclinical interstitial lung disease: The Multi-Ethnic Study of AtherosclerosisPurnema Madahar, Daniel A Duprez, Anna J Podolanczuk, et al.
Pageof 22